Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Amylyx Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Amylyx Pharmaceuticals's regulatory disclosures and financial reporting.
Amylyx Pharmaceuticals, Inc. (AMLX) director Karen Firestone reported exercising stock options to acquire common shares on August 31, 2026. She exercised two fully vested stock option grants covering a total of 50,000 shares of Common Stock, at exercise prices of $1.76 and $5.05 per share, respectively. The filing does not show her post-transaction share balances, and no Rule 10b5-1 trading plan is reported.
Amylyx Pharmaceuticals, Inc. (symbol: AMLX) is the issuer of record for a Form 4 filing submitted to the SEC.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Co-Chief Executive Officer and director Justin B. Klee acquired 60,039 shares of Common Stock on August 18, 2026 through a grant classified as a performance-based award. The shares are represented by performance share units that vested on that date. Following this award, Klee directly holds 3,643,520 shares of Amylyx Pharmaceuticals Common Stock.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Legal Officer Gina Mazzariello acquired additional equity-based compensation. On August 18, 2026, she received 21,284 shares of Common Stock represented by performance share units (PSUs) that were awarded upon the achievement of certain performance metrics and vested on that date. Following this award, she directly holds 200,374 shares of Amylyx Pharmaceuticals common stock.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Medical Officer Camille L. Bedrosian acquired 22,807 shares of common stock through a compensation-related grant. The shares are represented by performance share units (PSUs) that were awarded upon achievement of specified performance metrics and vested on August 18, 2026. Following this vesting, Bedrosian holds 288,092 common shares directly.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Co-Chief Executive Officer and director Joshua B. Cohen received an equity award linked to company performance. On August 18, 2026, he acquired 60,039 shares of Common Stock represented by performance share units (PSUs) that vested on that date upon achievement of specified performance metrics. Following this vesting event, Cohen directly holds 3,643,587 shares of Amylyx Common Stock.
Amylyx Pharmaceuticals, Inc. (AMLX) announced an underwritten public offering of 14,090,000 shares of common stock at $35.50 per share, with underwriters granted a 30-day option to purchase up to an additional 2,113,500 shares at the public price less underwriting discounts and commissions.
Amylyx expects to receive aggregate net proceeds of approximately $471.7 million, or approximately $542.5 million if the option is fully exercised. The company intends to use the net proceeds, together with existing cash, cash equivalents and marketable securities, to fund the potential U.S. commercial launch of avexitide, if approved, including additional manufacturing capacity, and for research and development, working capital and other general corporate purposes. The offering is expected to close on August 21, 2026, subject to customary closing conditions.
Amylyx Pharmaceuticals, Inc. (AMLX) is conducting a primary offering of 14,090,000 shares of common stock at a public offering price of $35.50 per share under its Form S-3 shelf registration. Underwriters have a 30-day option to purchase up to 2,113,500 additional shares at the public offering price less underwriting discounts and commissions.
Gross proceeds are expected to be $500.2 million (or $575.2 million if the option is exercised in full), with net proceeds to Amylyx of approximately $471.7 million (or $542.5 million with full option exercise) after underwriting discounts, commissions and estimated expenses. As of June 30, 2026, 111,368,283 shares of common stock were outstanding.
Amylyx plans to use the net proceeds, together with existing cash, cash equivalents and marketable securities, to fund the potential U.S. commercial launch of its lead investigational drug avexitide for post-bariatric hypoglycemia if approved, including securing commercial manufacturing capacity, and for research and development, working capital and other general corporate purposes. The company disclosed that the offering will cause immediate dilution of $29.83 per share to new investors based on the offering price.
Amylyx Pharmaceuticals, Inc. (AMLX) is conducting a primary offering of up to $350,000,000 of its common stock under an effective shelf registration. The shares trade on Nasdaq Global Select Market under the symbol AMLX, with a closing price of $35.11 on August 18, 2026.
Amylyx is a pre-commercial pharmaceutical company focused on endocrine and neurodegenerative diseases. Its lead asset, avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism, has U.S. FDA Breakthrough Therapy, Rare Pediatric Disease and Orphan Drug Designations. The Phase 3 LUCIDITY trial in PBH met its FDA-agreed primary endpoint, showing a 55% reduction in Level 2 and 3 hypoglycemic events versus placebo (p=0.000003), with a generally favorable safety profile.
The company plans to submit a New Drug Application for avexitide by the end of 2026 and is arranging commercial supply through contract manufacturers. Other programs include AMX0035 in Wolfram syndrome, AMX0114 in ALS, and long-acting GLP-1 antagonist AMX0318. Net proceeds will be used with existing cash to fund a potential U.S. avexitide launch, expand manufacturing capacity, and support R&D, working capital and general corporate purposes, while existing shareholders will experience dilution from this equity issuance.
Amylyx Pharmaceuticals, Inc. reported positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass. The randomized, double-blind, placebo-controlled study in 78 participants met its FDA-agreed primary endpoint with a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (rate ratio 0.45, 95% CI 0.32–0.63, p=0.000003), and met all secondary endpoints. Avexitide was generally well-tolerated, with no treatment-related serious adverse events and mostly mild or moderate side effects. PBH currently has no approved therapies and affects an estimated ~160,000 people in the U.S. Amylyx plans an NDA submission to the FDA by the end of 2026 and is preparing for a potential commercial launch of avexitide in 2027, supported by orphan drug designation, expected NCE exclusivity, and patent rights through 2037 with potential extensions.